SUPER CHICORÉE
Food supplement declared in France, decision dated 29 October 2026
SUPER CHICORÉE (Panda tea) is a food supplement declared in France. Status: declared in France, may be marketed. 1 rule of use applies to its ingredients (limits and warnings).
- Brand
- Panda tea
- Food business operator placing the product on the market
- PANDA SAS
- Status
- Declared in France, may be marketed: the authorities did not object to the declaration (this is neither an authorisation nor a safety assessment)
- Form
- Powder
- Daily dose
- 5,5g
- Directions for use
- Préparer 5,5 g de poudre, soit 1 cuillère doseuse légèrement bombée. Ajouter la poudre dans votre tasse puis verser 200 mL d’eau chaude ou froide. Bien mélanger.
- Intended populations
- General population, Men and women aged 18 and over
- Not recommended (according to the manufacturer)
- Adolescents (under 18), Breastfeeding women, Children (under 12), Young children (aged 1 to 3), Pregnant women, Infants (under 1 year), Heart problems, Liver problems, Taking antidepressants, Taking thyroid medication, Children (under 6), Children (under 10)
- Objectives stated by the manufacturer (these are not authorised claims)
- Mémoire, Digestion, Autre : Energie
Declaration 380711, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 15 November 2026.
Declared composition
Plants
| Plant | Part | Preparation | Per day |
|---|---|---|---|
| Hericium erinaceus | Carpophore | Extrait sec aqueux | 636 mg |
| Ganoderma lucidum(Curtis ex Fr.) P.Karst. | Carpophore | Extrait sec aqueux | 477 mg |
| Ophiocordyceps sinensis | Mycélium | Extrait sec aqueux | 180 mg |
| Foeniculum vulgare Mill. | Fruit | Extrait sec aqueux | 128 mg |
| Withania somnifera (L.) Dunal | Racine | Extrait sec aqueux | 50 mg |
Other active ingredients
| Name | Per day |
|---|---|
| Fibres solubles d'acacia | not declared |
| Fibres solubles de maïs | not declared |
Vitamins and minerals
Compl'Alim does not publish vitamin and mineral doses. The references below help you read the product label: EFSAEuropean Food Safety Authority. safety limit for adults and maximum dose set in France per product (Order of 9 May 2006, not revised since November 2006).
| Declared form | Nutrient | EFSA limit, adults | Maximum dose in France |
|---|---|---|---|
| D-pantothénate de calcium | Acide pantothénique (vitamine B5) | pas de limite (données insuffisantes) | dose annulled by the French Council of State in 2011 |
| D-biotine | Biotine (vitamine B8) | pas de limite (données insuffisantes) | dose annulled by the French Council of State in 2011 |
| Acide ptéroylmonoglutamique | Folates (vitamine B9) | 1,000 µg | 200 µg |
| Nicotinamide | Nicotinamide (vitamine B3) | 900 mg | 54 mg |
| Chlorhydrate de thiamine | Vitamine B1 (thiamine) | pas de limite (données insuffisantes) | dose annulled by the French Council of State in 2011 |
| Cyanocobalamine | Vitamine B12 | pas d'effet indésirable défini | dose annulled by the French Council of State in 2011 |
| Riboflavine | Vitamine B2 (riboflavine) | pas de limite (données insuffisantes) | dose annulled by the French Council of State in 2011 |
| Chlorhydrate de pyridoxine | Vitamine B6 | 12 mg | 2 mg |
| Acide L-ascorbique | Vitamine C | pas de limite (données insuffisantes) | 180 mg |
Other ingredients
Myristica fragrans Houtt., Curcuma longa L., Syzygium aromaticum (L.) Merr. & L.M.Perry, Cinnamomum burmanni (Nees & T.Nees) Blume, Zingiber officinale Roscoe, Cichorium intybus L., poudre de cacao
List from the declaration, administrative decision dated (Compl'Alim, food supplement declarations (France)).
Has the product changed? Photograph the packaging.
Label warnings
Déconseillé aux enfants de moins de 18 ans et aux femmes enceintes ou allaitantes. Déconseillé en cas d’allergie croisée connue, en particulier aux plantes de la famille des Asteraceae et des Apiaceae (anis, céleri…) ou au pollen d’armoise ou à l’anéthole. Déconseillé aux personnes atteintes de troubles endocriniens (particulièrement les dysthyroïdies et l’hyperandrogénie) et de troubles hépatiques ou cardiaques. Demander conseil à un professionnel de santé avant toute prise en association avec des substances à action dépressive du système nerveux central, ou en cas de conduite de véhicules ou de machines.
Regulatory points
- Conditions légales
Foeniculum vulgare Mill.: La portion journalière recommandée ne doit pas conduire à une ingestion d'estragole supérieure à 0,05 mg/kg de poids corporel pour les enfants de moins de 12 ans.
Source: French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, arrêté du 24 juin 2014, annexe I.
This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.
Official warnings (Health Canada)
Health Canada publishes warnings on these ingredients:
- Foeniculum vulgare Mill.
Read the warning, when it applies and the studies cited
BITTER FENNEL- FOENICULUM VULGARE
Route of administration: Oral
Cautions and warnings
Condition of application: All products.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (EMA 2024, 2007).
Sources cited by Health Canada (2)
- EMA 2024. European Medicines Agency. Community Monograph on Foeniculum vulgare Miller subs. vulgare var. vulgare. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 31 January 2024. [Accessed 2024 March 14]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-foeniculum-vulgare-miller-subsp-vulgare-var-vulgare-fructus_en.pdf
- EMA 2007. European Medicines Agency. Community Monograph on Foeniculum vulgare Miller subs. vulgare var. vulgare oil. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 5 July 2007. [Accessed 2024 March 1]. Available from: http://www.e-lactancia.org/media/papers/Fennel-DS-EMEA2007.pdf
Condition of application: Essential oil and Tincture.
Ask a health care practitioner before use if you are taking any medications including birth control pills or hormone therapy or other health products (EMA 2007).
Sources cited by Health Canada (1)
- EMA 2007. European Medicines Agency. Community Monograph on Foeniculum vulgare Miller subs. vulgare var. vulgare oil. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 5 July 2007. [Accessed 2024 March 1]. Available from: http://www.e-lactancia.org/media/papers/Fennel-DS-EMEA2007.pdf
Known adverse reactions
Stop use if hypersensitivity/allergy occurs (EMA 2024, 2007).
Sources cited by Health Canada (2)
- EMA 2024. European Medicines Agency. Community Monograph on Foeniculum vulgare Miller subs. vulgare var. vulgare. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 31 January 2024. [Accessed 2024 March 14]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-foeniculum-vulgare-miller-subsp-vulgare-var-vulgare-fructus_en.pdf
- EMA 2007. European Medicines Agency. Community Monograph on Foeniculum vulgare Miller subs. vulgare var. vulgare oil. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 5 July 2007. [Accessed 2024 March 1]. Available from: http://www.e-lactancia.org/media/papers/Fennel-DS-EMEA2007.pdf
Health Canada monograph dated 29 November 2024
SWEET FENNEL -FOENICULUM VULGARE
Route of administration: Oral
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (EMA 2024).
Sources cited by Health Canada (1)
- EMA 2024. European Medicines Agency. Community Monograph on Foeniculum vulgare Miller. subsp. vulgare var. dulce (Mill.) Batt. & Trab., Fructus London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 31 January 2024. [Accessed 2024 March 14]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-foeniculum-vulgare-miller-subsp-vulgare-var-dulce-mill-batt-trab-fructus-revision-1_en.pdf
Known adverse reactions
Stop use if hypersensitivity/allergy occurs (EMA 2024).
Sources cited by Health Canada (1)
- EMA 2024. European Medicines Agency. Community Monograph on Foeniculum vulgare Miller. subsp. vulgare var. dulce (Mill.) Batt. & Trab., Fructus London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 31 January 2024. [Accessed 2024 March 14]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-foeniculum-vulgare-miller-subsp-vulgare-var-dulce-mill-batt-trab-fructus-revision-1_en.pdf
- Withania somnifera (L.) Dunal
Read the warning, when it applies and the studies cited
ASHWAGANDHA - WITHANIA SOMNIFERA
Route of administration: Oral
Cautions and warnings
Condition of application: General debility; Memory enhancement; Adaptogen; Restlessness/nervousness.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Condition of application: All products.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Upton 2000; McGuffin et al. 1997).
Sources cited by Health Canada (3)
- McGuffin M, Hobbs C, Upton R, Goldberg A, editors. American Herbal Products Association's Botanical Safety Handbook. Boca Raton (FL): CRC Press, LLC; 1997.
- Upton R, editor. American Herbal Pharmacopoeia and Therapeutic Compendium: Ashwagandha Root (Withania somnifera) - Standards of Analysis, Quality Control, and Therapeutics. Santa Cruz (CA): American Herbal Pharmacopoeia; 2000.
- Berardi RR, DeSimone EM, Newton GD, Oszko MA, Popovich NG, Rollins CJ, Shimp LA, Tietze K, éditeurs. Handbook of Nonprescription Drugs: An Interactive Approach to Self-Care, 13e édition. Washington (DC) : American Pharmaceutical Association; 2002.
When using this product exercise caution if you drive or use machinery as you may experience drowsiness (Berardi et al. 2002).
Sources cited by Health Canada (3)
- Berardi RR, DeSimone EM, Newton GD, Oszko MA, Popovich NG, Rollins CJ, Shimp LA and Tietze KJ, editors. Handbook of Nonprescription Drugs: An Interactive Approach to Self-Care, 13th edition. Washington (DC): American Pharmaceutical Association; 2002.
- McGuffin M, Hobbs C, Upton R, Goldberg A, éditeurs. American Herbal Products Association's Botanical Safety Handbook. Boca Raton (FL) : CRC Press, LLC; 1997.
- Upton R, éditeur. Ashwagandha Root, Withania somnifera Analytical, Quality Control, And Therapeutic Monograph. Santa Cruz (CA) : American Herbal Pharmacopoeia and Therapeutic Compendium; 2000.
They concern the ingredient, not this product or its dose. They do not replace medical advice.
Brand : Panda tea
Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.